1. Aged 30–60 years 2. Diagnosed with uncontrolled or poorly controlled type 2 diabetes (HbA1c >8.0%, or fasting plasma glucose =10 mmol/L, or 2-hour post-breakfast glucose =12 mmol/L) 3. Diagnosed with uncontrolled hypertension (SBP >140 mmHg or DBP >90 mmHg) 4. On stable oral anti-diabetic and anti-hypertensive therapy for at least 60 days prior to enrolment 5. Willing and able to provide informed consent Other
Conditions
Interventions
Intervention group: SuperWater® enriched with Aeon HD® (zinc sulfate heptahydrate, chromium picolinate, magnesium sulfate, vanadium (IV) oxide sulfate hydrate, potassium sulfate, sodium selenate)
200 ml, three times daily for 12 weeks.
Control group: Equivalent volume of normal filtered water.
Adherence will be monitored through weekly contact and consumption logs.
Participants will be rand
however, due to the nature of the intervention, investigators responsible for distribution of water cannot be blinded. Outcome assessors and laboratory staff will remain blinded to treatment assignmen
Sponsors
Aquanimity Bangladesh Ltd
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Diabetes and hypertension
Exclusion criteria
Exclusion criteria: 1. Decline participation or fail to provide consent 2. Pregnant or lactating women, or planning pregnancy during the study 3. Acute renal failure, liver disease, or severe metabolic disorder 4. Insulin use for >1 week before enrolment 5. Major surgery, acute infection, or pancreatitis within the last 3 months 6. Mental health conditions limiting participation 7. Not residing in Dhaka during the study period 8. Normotensive or untreated hypertensive individuals
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline and 3 months: 1. Fasting plasma glucose (mmol/L) measured using enzymatic laboratory assay after 8–12 hours fasting 2. Lipid profile (TC, LDL-C, HDL-C, TG; mmol/L) measured using automated biochemistry analyzer using enzymatic colorimetric methods 3. Serum creatinine (mg/dL or µmol/L) measured using laboratory kinetic Jaffe or enzymatic assay 4. SGPT/ALT (U/L) measured using biochemistry analyzer using kinetic UV method 5. Proportion achieving glycaemic control (HbA1c < 7%) derived from lab-measured HbA1c 6. Proportion achieving blood pressure control (<140/90 mmHg) derived from automated BP readings 7. Body weight and BMI (kg, kg/m²) measured using digital scale, stadiometer; BMI calculated as kg/m² 8. Daily water intake (liters/day) measured using structured hydration questionnaire and intake log 9. Adverse events measured using structured adverse event reporting form reviewed at follow-up | — |
Countries
Bangladesh
Contacts
Public ContactBishwajit Bhowmik
Outcome results
None listed